Skip to main content

Table 2 Biomarker results by subgroup

From: Mammostrat®as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Biomarker

All cases

All ER-positive

ER-positive tamoxifen onlya

ER-positive, node-negative, tamoxifen onlya

SLC7A5

    

   0

1231 (79.9%)

1035 (87.0%)

732 (88.1%)

578 (88.0%)

   1

139 (9.0%)

77 (6.5%)

51 (6.1%)

38 (5.8%)

   2

41 (2.7%)

24 (2.0%)

11 (1.3%)

9 (1.4%)

   Missingb

129 (8.4%)

53 (4.5%)

37 (4.5%)

32 (4.9%)

HTF9C

    

   0

1234 (80.1%)

1015 (85.4%)

712 (85.7%)

559 (85.1%)

   1

103 (6.7%)

69 (5.8%)

43 (5.2%)

35 (5.3%)

   2

72 (4.7%)

46 (3.9%)

36 (4.3%)

25 (3.8%)

   Missing

131 (8.5%)

59 (5.0%)

40 (4.8%)

38 (5.8%)

NDRG1

    

   0

1085 (70.5%)

904 (76.0%)

624 (75.1%)

495 (75.3%)

   1

175 (11.4%)

127 (10.7%)

96 (11.6%)

75 (11.4%)

   2

148 (9.6%)

100 (8.4%)

66 (7.9%)

47 (7.2%)

   Missing

132 (8.6%)

58 (4.9%)

45 (5.4%)

40 (6.1%)

CEACAM5

    

   0

1251 (81.2%)

1005 (84.5%)

699 (84.1%)

550 (83.7%)

   1

75 (4.9%)

67 (5.6%)

46 (5.5%)

39 (5.9%)

   2

77 (5.0%)

61 (5.1%)

44 (5.1%)

29 (4.4%)

   Missing

137 (8.9%)

56 (4.7%)

44 (5.3%)

39 (5.9%)

P53

    

   0

1040 (67.5%)

884 (74.3%)

619 (74.5%)

479 (72.9%)

   1

229 (14.9%)

166 (14.0%)

119 (14.3%)

101 (15.4%)

   2

117 (7.6%)

67 (5.6%)

39 (4.7%)

30 (4.6%)

   Missing

154 (10.0%)

72 (6.1%)

54 (6.5%)

47 (7.2%)

LMH

    

   Low

717 (46.6%)

643 (54.1%)

444 (53.4%)

341 (51.9%)

   Medium

305 (19.8%)

244 (20.5%)

175 (21.1%)

139 (21.2%)

   High

278 (18.1%)

168 (14.1%)

112 (13.5%)

88 (13.4%)

   Missing

240 (15.6%)

134 (11.3%)

100 (12.0%)

89 (13.5%)

Total

1300

1055

731

568

  1. ER, estrogen receptor; LMH, low, medium, or high. aTamoxifen only, patients treated with adjuvant tamoxifen without adjuvant chemotherapy. bMissing data due to loss of cores from tumor microarrays or no tumor in the tumor microarray core.